Drug discovery efforts targeting prostate cancer have focused on androgen deprivation therapy, androgen biosynthesis inhibitors, AR antagonists, AR degraders, and agents that disrupt N-terminal and C-terminal interactions [2]. Here, AR is linked to Familial prostate cancer.